showed that liraglutide and exendin-4 could increase osteoclast number but reduce the bone resorbed area per osteoclast in vivo [68]
Clinical trials such as SURMOUNT-1 showed substantial weight loss in participants without diabetes, with average reductions of roughly 16-22% body weight over 72 weeks
The mRNA levels of key genes in these pathways, such as Sqle, Dhcr7, Cyp51, Shc2, Hspa1a , and Hspa1l , were significantly different between EGCG-treated mice and HFHC mice as well (Figures 8F,G)
Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health in North Carolina, questioned whether the increased risk was due to the rapid weight loss or some other mechanism of the drug
2021 Dec 8;22(24):13205